In Brief: FDA Orthopedic and Rehabilitation Devices Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA Orthopedic and Rehabilitation Devices Panel: Agenda for Jan. 12-13 meeting at FDA's Parklawn Building in Rockville, Maryland has been rearranged with discussion of a reclassification petition for constrained elbows moved up one day to Jan. 12, along with originally scheduled petitions for non-and semi-constrained shoulders. Renew of petitions for patellofemoral knees and uni- and total patellofemorotibial knees has been rescheduled from Jan. 12 to Jan. 13, alongside the originally planned discussion of the classification of calcium sulfate pre-formed pellets (plaster of paris pellets). Contact panel secretary Jodi Nashman at 301/594-2036 for further information...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.